These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28753870)

  • 1. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
    Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.
    Veitonmäki T; Murtola TJ; Määttänen L; Taari K; Stenman UH; Tammela TL; Auvinen A
    Br J Cancer; 2014 Sep; 111(7):1421-31. PubMed ID: 25010865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of prostate cancer screening among men using antidiabetic medication.
    Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
    Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
    J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
    Platz EA; Rohrmann S; Pearson JD; Corrada MM; Watson DJ; De Marzo AM; Landis PK; Metter EJ; Carter HB
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):390-6. PubMed ID: 15734963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial.
    Veitonmäki T; Murtola TJ; Talala K; Taari K; Tammela T; Auvinen A
    PLoS One; 2016; 11(4):e0153413. PubMed ID: 27100876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
    Vettenranta A; Murtola TJ; Raitanen J; Raittinen P; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    JAMA Oncol; 2022 Jan; 8(1):61-68. PubMed ID: 34817559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
    Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
    Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
    Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
    Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy.
    Bhindi B; Margel D; Hamilton RJ; Fernandes KA; Trottier G; Hersey KM; Finelli A; Trachtenberg J; Zlotta A; Kulkarni GS; Toi A; Evans A; van der Kwast TH; Fleshner NE
    Urology; 2014 Nov; 84(5):1073-80. PubMed ID: 25443907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
    Murad AS; Down L; Davey Smith G; Donovan JL; Athene Lane J; Hamdy FC; Neal DE; Martin RM
    Int J Cancer; 2011 Mar; 128(6):1442-8. PubMed ID: 20506261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.